Nature communications · 2023
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uraki Ryuta, Iida Shun, Halfmann Peter J, Yamayoshi Seiya, Hirata Yuichiro, Iwatsuki-Horimoto Kiyoko, Kiso Maki, Ito Mutsumi, Furusawa Yuri, Ueki Hiroshi, Sakai-Tagawa Yuko, Kuroda Makoto, Maemura Tadashi, Kim Taksoo, Mine Sohtaro, Iwamoto Noriko, Li Rong, Liu Yanan, Larson Deanna, Fukushi Shuetsu, Watanabe Shinji, Maeda Ken, Wang Zhongde, Ohmagari Norio, Theiler James, Fischer Will, Korber Bette, Imai Masaki, Suzuki Tadaki, Kawaoka Yoshihiro
Аннотация
The prevalence of the Omicron subvariant BA.2.75 rapidly increased in India and Nepal during the summer of 2022, and spread globally. However, the virological features of BA.2.75 are largely unknown. Here, we evaluated the replicative ability and pathogenicity of BA.2.75 clinical isolates in Syrian hamsters. Although we found no substantial differences in weight change among hamsters infected with BA.2, BA.5, or BA.2.75, the replicative ability of BA.2.75 in the lungs is higher than that of BA.2 and BA.5. Of note, BA.2.75 causes focal viral pneumonia in hamsters, characterized by patchy inflammation interspersed in alveolar regions, which is not observed in BA.5-infected hamsters. Moreover, in competition assays, BA.2.75 replicates better than BA.5 in the lungs of hamsters. These results suggest that BA.2.75 can cause more severe respiratory disease than BA.5 and BA.2 in a hamster model and should be closely monitored.